Clinical Trial Detail

NCT ID NCT03218683
Title Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

CLL/SLL

multiple myeloma

peripheral T-cell lymphoma

non-Hodgkin lymphoma

Richter's syndrome

Therapies

AZD5991

Age Groups:

No variant requirements are available.